

Presentation of The good story of dogs who helped pharmacologists in the discovery of a new drug against Leishmaniasis

11.06.2019

The New Medicines for Trypanosomatidic Infections (NMTrypI) 2014-2017. GA603240. FP7 European project presents the video about the dog trial performed during the project implementation: (dog trial of NMT-A2) and its 2 years follow-up after the project end (2018-2019).



NT
MIp



STOP LEISH

The good story of dogs who helped pharmacologists in the discovery of a new drug against Leishmaniasis

The New Medicine for Trypanosomatidic infection research exploitation

EUROPEAN PROJECT NMTRYPI (NEW MEDICINE FOR TRYPANOSOMATIDIC INFECTIONS)
(7 FRAMEWORK PROGRAMME - FP7 HEALTH)

Video link: <https://www.youtube.com/watch?v=9w5V-fIKZPU>

Participants to the NMTrypI project:

University of Modena and Reggio Emilia, (UniMORE), Italy, coordination; National Hellenic Research Foundation, (NHRF), Greece; University of Siena (UNISI), Italy; Fraunhofer Institute for Molecular Biology and Applied Ecology-ScreeningPort (Fraunhofer), Germany; Institute for Molecular and Cell Biology, (IBMC), Portugal; Tydock Pharma srl. (TYDOCK), Italy; Hypha Discovery Ltd, (Hypha), United Kingdom; National Center for Research (NCR), Sudan; Heidelberg Institute for Theoretical Studies (HITS), Germany; Bernhard Nocht Institute for Tropical Medicine (BNI) Germany; Complutense University of Madrid (UCM), Spain; Centro de Pesquisa em Energia e Materiais (CNPEM), Brazil.

The trial of NMT-A2 on dogs was performed during the project to study the efficacy of the new candidate (drug lead), namely NMT-A2, progressed from the early phases of the discovery pipeline to the final pre-clinical phase.

Dr.Theodora Calogeropoulou, NHRF (Greece) designed and synthesized the compound and project participants contributed to the project success.

Prof. Josè Alunda performed the dogs trial at University Complutense of Madrid (UCM) and supervised the dogs' follow-up after the project end.

At the end of the successful trial, dogs were given for adoption after Regional entity approval and were subjected to a follow-up study. The post-treatment study of 2 years allowed the evaluation of the long-term positive impact of our drug candidate on the dogs adopted.

Websites of reference:

- NMTrypY website: <https://fp7-nmtrypi.eu/>
- EU website of NMTrypI: <https://cordis.europa.eu/project/rcn/109924/factsheet/en>
- NMTrypI SEEK database: <https://fp7h-synergy.h-its.org>
- Synergy activity meeting:
http://cdm.unimo.it/home/dipfarm/costi.mariapaola/NPDs_Synergy-meeting_2016_home-it.html